Navigation Links
Researchers design drug to restore cell suicide in HPV-related head and neck cancer
Date:4/8/2013

the function of the p53 "tumor-suppressor" gene and triggers the death of the cancer cells.

"Our study revealed a new mechanism for p53 inactivation in HPV-positive head and neck cancer, and this allowed us to develop an agent that disrupts that interaction and reactivates p53 in HPV-positive head and neck cancer," Pan says. "Our pre-clinical studies show CH1iB can reactivate p53 and eliminate HPV-positive head and neck cancer cells."

Pan notes that the standard of care for HPV-positive head and neck cancer uses high-dose cis-platinum, a chemotherapy drug that causes serious side effects that are difficult for patients to tolerate. The drug's toxicity raises the need for safer therapy, and, although further testing is necessary, combining CH1iB with a low dose of cis-platinum might one day provide an alternative.

For this study, Pan and his colleagues used high-risk HPV-positive head and neck squamous cell carcinoma cells. Key technical findings include:

  • The small-molecule inhibitor CH1iB inhibits the binding of the HPV E6 protein with the p300 cell protein;

  • The binding of the CH1iB inhibitor with p300 reactivated p53 and dramatically potentiated the efficacy of cis-platinum in HPV-positive head and neck cancer cells.

  • The combination of CH1iB and cis-platinum eliminated 91 percent of HPV16-positive head and neck cancer cells; it also increased apoptosis by 984 percent and 443 percent compared with CH1iB and cis-platinum respectively alone.

"These results suggest that fewer cycles or a tapered dose of cis-platinum, along with a CH1 inhibitor, might be sufficient to effectively manage HPV-positive head and neck cancer patients and offer a better toxicity profile," Pan says.

"Taken together, our data suggest that we've discovered a novel approach for reactivating the p53 gene in HPV-positive head and neck cancer that may translate to other HPV-positive carcinomas."


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers shine light on how stress circuits learn
2. Cleveland Clinic researchers discover new link between heart disease and red meat
3. SFU researchers help unlock pine beetles Pandoras box
4. Empa researchers join Quantis to open new branch in Switzerland
5. MDC and FMP researchers identify edema inhibitor
6. Barrow researchers identify
7. Researchers discover brain cancer treatment using genetic material from bone marrow cells
8. Notre Dame researchers are using new technologies to combat invasive species
9. University of Montreal researchers discover how drug prevents aging and cancer progression
10. Researchers question evaluation methods for protected areas in the Amazon
11. Penn Researchers attach Lyme disease antibodies to nanotubes, paving way for diagnostic device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... University of Manchester scientists have discovered for the first time ... (HPV) triggers cancer in what could lead to new treatments ... to increase the risk of developing cancers of the cervix ... accounting for approximately 70% of all cervical cancer cases. ...
... , This release is available in Spanish ... Biology and Regenerative Medicine (CABIMER) and the University of ... apoptosis is not only essential in breast tumor cells resistance ... potential against cancer), but this protein is also key to ...
... NY - One big challenge in converting plants to biofuels ... up make it hard to break them down. Now scientists ... are unraveling details of how plant cells, structural supports - ... finding ways to change their composition for more efficient biofuel ...
Cached Biology News:Scientists identify how virus triggers cervical and mouth cancer 2A protein called cFLIP makes tumor cells in breast cancer resistant to treatments 2Scientists unravel more details of plant cell-wall construction 2
(Date:7/28/2015)... , July 28, 2015 Deerfield Management ... Healthcare Innovations Fund, L.P., which will invest in groundbreaking ... in genetic diseases, cancer, and orphan diseases. The venture ... transform how therapeutics are developed and improve the way ... one of the largest healthcare-focused venture funds in the ...
(Date:7/28/2015)... SAN DIEGO , July 28, 2015  Kerastem ... conditional approval from the U.S. FDA Center For Biologics ... Gene Therapies to conduct a clinical trial investigating the ... treatment of female and early male pattern baldness (androgenic ... the STYLE trial, follows initial clinical work in ...
(Date:7/28/2015)... BEACH, Calif. , July 28, 2015 /PRNewswire-USNewswire/ ... announced that it has hit a milestone of ... Signafuse was FDA 510(k) cleared in early 2014 ... use in posterolateral spine fusion procedures.  This is ... products, as less than 6% of new synthetic ...
(Date:7/28/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... granted to German life sciences entrepreneurs with a ... of biotechnology (collectively, the "Optionee"), an option to ... vaccine technology (the "Technology"), including AEZS-120, the most ... ready to enter a Phase 1 clinical trial. ...
Breaking Biology Technology:Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3Kerastem Receives Conditional Approval from FDA for Alopecia Trial 2Revolutionary Bone Graft Exceeds Expectations 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 2Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology 3
... CITY, Calif., Sept. 13 Abaxis, Inc.,(Nasdaq: ... analysis systems, announced today that Clint Severson, CEO ... LLC Sixth Annual San,Francisco Institutional Investor Forum Conference ... Time at The Ritz-Carlton Hotel in San Francisco. ...
... JOSE, Calif., Sept. 13 Micrus,Endovascular Corporation (Nasdaq: ... of Stockholders will be broadcast live over the,Internet on ... (9:00,a.m. Pacific time). Those listening to the meeting via ... ask questions during the,meeting. What: Micrus Endovascular ...
... Exchange Agreement, COPENHAGEN, September 13 Genmab ... asset exchange agreement with,Medarex, Inc. Under the terms ... HuMax-Inflam(TM)/MDX-018, which targets IL-8, and Medarex will,receive full ... and,Medarex will release to each other all previously ...
Cached Biology Technology:Micrus Endovascular to Webcast Fiscal 2007 Annual Meeting of Stockholders 2Genmab Announces Asset Exchange Agreement 2
Bovine Coronary Artery Endothelial Cells (BCAEC) (>500,000 cells)...
... Receptor antiserum This NPY Y2 antibody ... and is currently being characerized in brain. The ... mouse and appears to work better on mose ... For full characterizarion in dorsal root ganglion and ...
... allows the Thermo-Fast® 96 ... PCR plates to be ... PRISM® 3700 capillary sequencer. ... information on the software ...
... beta Synuclein Synucleins are small, soluble ... in certain tumors. The family includes three ... gamma synuclein. The alpha and beta synuclein ... where they are seen mainly in presynaptic ...
Biology Products: